210 related articles for article (PubMed ID: 2701574)
1. Optimal management of nausea and vomiting in clinical oncology.
Briscoe K
Oncology (Williston Park); 1989 Aug; 3(8 Suppl):11-5. PubMed ID: 2701574
[TBL] [Abstract][Full Text] [Related]
2. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced nausea and vomiting. Easing patients' fear and discomfort with effective antiemetic regimens.
Bilgrami S; Fallon BG
Postgrad Med; 1993 Oct; 94(5):55-8, 62-4. PubMed ID: 8415336
[TBL] [Abstract][Full Text] [Related]
4. Acute and delayed nausea and emesis control in pediatric oncology patients.
Holdsworth MT; Raisch DW; Frost J
Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
6. Optimising antiemetic therapy: what are the problems and how can they be overcome?
Aapro M
Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
[TBL] [Abstract][Full Text] [Related]
7. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
Jordan K; Kasper C; Schmoll HJ
Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
[TBL] [Abstract][Full Text] [Related]
9. [Management of emesis in cancer patients].
Slimane K; Perez A; Ruffié P; di Palma M
Bull Cancer; 2004 May; 91(5):403-8. PubMed ID: 15281279
[TBL] [Abstract][Full Text] [Related]
10. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy induced-vomiting--a practical guide for prevention and therapy].
Jordan K; Voigt W; Schmoll HJ
Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1869-72. PubMed ID: 16915549
[TBL] [Abstract][Full Text] [Related]
12. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
13. Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. The Belgian Navoban Group.
Van Belle SJ; Cocquyt VF; Bleiberg H; Canon JL; Buyse M; Hulstaert F; De Witte M; De Keyser P; Westelinck K
Anticancer Drugs; 1995 Feb; 6 Suppl 1():22-30. PubMed ID: 7749166
[TBL] [Abstract][Full Text] [Related]
14. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
15. [Modern aspects of antiemetic therapy].
Aleksandrović J; Dagović A; Jeremić B
Srp Arh Celok Lek; 1998; 126(7-8):295-303. PubMed ID: 9863398
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting.
Goodman M
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):20-32. PubMed ID: 9282378
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of antiemetic drugs.
Jordan K; Schmoll HJ; Aapro MS
Crit Rev Oncol Hematol; 2007 Feb; 61(2):162-75. PubMed ID: 17208005
[TBL] [Abstract][Full Text] [Related]
18. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
19. Clinical practice guidelines on antiemetics in oncology.
Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
[TBL] [Abstract][Full Text] [Related]
20. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
